EP2994130A4 - Fgf modulation of in vivo antibody production and humoral immunity - Google Patents

Fgf modulation of in vivo antibody production and humoral immunity Download PDF

Info

Publication number: EP2994130A4
Authority: EP; European Patent Office
Prior art keywords: fgf; modulation; antibody production; humoral immunity; vivo antibody
Prior art date: 2013-05-06
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP13884155.6A

Other languages

German (de)

French (fr)

Other versions

EP2994130A1 (en

Inventor

Andrew B. BUSH

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Individual

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-05-06

Filing date

2013-05-06

Publication date

2017-02-22

2013-05-06 Application filed by Individual filed Critical Individual

2016-03-16 Publication of EP2994130A1 publication Critical patent/EP2994130A1/en

2017-02-22 Publication of EP2994130A4 publication Critical patent/EP2994130A4/en

Status Withdrawn legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Virology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)

EP13884155.6A 2013-05-06 2013-05-06 Fgf modulation of in vivo antibody production and humoral immunity Withdrawn EP2994130A4 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
PCT/US2013/039758 WO2014182277A1 (en)	2013-05-06	2013-05-06	Fgf modulation of in vivo antibody production and humoral immunity

Publications (2)

Publication Number	Publication Date
EP2994130A1 EP2994130A1 (en)	2016-03-16
EP2994130A4 true EP2994130A4 (en)	2017-02-22

Family

ID=51867595

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP13884155.6A Withdrawn EP2994130A4 (en)	2013-05-06	2013-05-06	Fgf modulation of in vivo antibody production and humoral immunity

Country Status (3)

Country	Link
EP (1)	EP2994130A4 (en)
JP (1)	JP2016520060A (en)
WO (1)	WO2014182277A1 (en)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2896247B1 (en) *	2006-01-13	2008-02-29	Sanofi Aventis Sa	FGFS RECEPTOR AGONISTIC DIMERS (FGFRS), PREPARATION METHOD AND THERAPEUTIC USE THEREOF

2013
- 2013-05-06 EP EP13884155.6A patent/EP2994130A4/en not_active Withdrawn
- 2013-05-06 JP JP2016512884A patent/JP2016520060A/en active Pending
- 2013-05-06 WO PCT/US2013/039758 patent/WO2014182277A1/en not_active Ceased

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ENRIQUE A. MESRI ET AL: "Kaposi's sarcoma and its associated herpesvirus", NATURE REVIEWS. CANCER, vol. 10, no. 10, 1 October 2010 (2010-10-01), GB, pages 707 - 719, XP055331485, ISSN: 1474-175X, DOI: 10.1038/nrc2888 *
GUDRUN ASCHERL ET AL: "Serum Concentrations of Fibroblast Growth Factor 2 Are Increased in HIV Type 1-Infected Patients and Inversely Related to Survival Probability", AIDS RESEARCH AND HUMAN RETROVIRUSES., vol. 17, no. 11, 20 July 2001 (2001-07-20), US, pages 1035 - 1039, XP055331461, ISSN: 0889-2229, DOI: 10.1089/088922201300343717 *
See also references of WO2014182277A1 *

Also Published As

Publication number	Publication date
JP2016520060A (en)	2016-07-11
EP2994130A1 (en)	2016-03-16
WO2014182277A1 (en)	2014-11-13

Publication	Publication Date	Title
IL279767B (en)	2021-09-30	Therapeutic polymeric nanoparticles and methods of making and using same
IL236183A0 (en)	2015-01-29	Engineered three-dimensional connective tissue constructs and methods of making the same
EP3708210B8 (en)	2022-11-16	Patient interface and aspects thereof
EP3663405B8 (en)	2024-10-30	Protein enriched microvesicles and methods of making and using the same
EP3068240A4 (en)	2017-06-14	Theacrine-based supplement and method of use thereof
EP3038659A4 (en)	2017-07-26	Engineered anti-dll3 conjugates and methods of use
EP3065776A4 (en)	2017-04-19	Novel anti-claudin antibodies and methods of use
EP3060136A4 (en)	2017-06-21	Support devices and methods of making and using them
EP3080607A4 (en)	2017-07-12	Novel anti-dpep3 antibodies and methods of use
EP3065875A4 (en)	2018-02-07	Bioprinter and methods of using same
EP3033097A4 (en)	2017-01-25	Factor viii-xten fusions and uses thereof
EP3015251A4 (en)	2017-01-11	Three-dimensional shaped body and support formation method
EP3079719B8 (en)	2019-12-04	Anti-siglec-8 antibodies and methods of use thereof
EP3038634A4 (en)	2017-10-11	Novel sez6 modulators and methods of use
EP3060253A4 (en)	2017-05-17	ANTI-Ly6E ANTIBODIES AND METHODS OF USE
EP3053978A4 (en)	2017-03-22	Polishing composition and production method therefor
EP3000439A4 (en)	2017-01-18	Maxillomandibular prosthesis and production method
WO2014144061A9 (en)	2014-12-11	Flavivirus neutralizing antibodies and methods of use thereof
EP2979984B8 (en)	2020-02-26	Delamination container and method of producing the same
EP3053977A4 (en)	2017-03-29	Polishing composition and production method therefor
EP3027182A4 (en)	2017-04-12	Novel copper-cysteamine and methods of use
EP3043805A4 (en)	2017-05-31	Biologic prosthesis and methods of production and use
EP3060061A4 (en)	2017-05-03	Use of probiotics in meat
EP3068874A4 (en)	2017-04-26	Fibroblast mixtures and methods of making and using the same
EP3071390A4 (en)	2017-08-16	Novel wheel and methods of production

Legal Events

Date	Code	Title	Description
2016-02-12	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2016-03-16	17P	Request for examination filed	Effective date: 20151204
2016-03-16	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2016-03-16	AX	Request for extension of the european patent	Extension state: BA ME
2016-08-10	DAX	Request for extension of the european patent (deleted)
2017-02-22	A4	Supplementary search report drawn up and despatched	Effective date: 20170119
2017-02-22	RIC1	Information provided on ipc code assigned before grant	Ipc: A61P 43/00 20060101ALI20170113BHEP Ipc: A61K 31/496 20060101ALI20170113BHEP Ipc: A61K 31/519 20060101ALI20170113BHEP Ipc: A61K 31/365 20060101ALI20170113BHEP Ipc: A61K 31/4709 20060101ALI20170113BHEP Ipc: A61K 31/405 20060101AFI20170113BHEP Ipc: A61K 31/5025 20060101ALI20170113BHEP Ipc: A61K 31/506 20060101ALI20170113BHEP Ipc: A61K 31/513 20060101ALI20170113BHEP Ipc: A61K 31/403 20060101ALI20170113BHEP
2018-02-02	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
2018-03-07	18D	Application deemed to be withdrawn	Effective date: 20170818